CAJ | 학술논문

目的检测脑胶质瘤组织中Aurora-A的表达及其与患者各临床参数之间的关系.方法选取肇庆市第一人民医院神经外科自2010年6月至2012年8月的40例脑胶质瘤石蜡存档手术标本,其中WHO分级Ⅰ级8例、Ⅱ级8例、Ⅲ级10例、Ⅳ级14例.采用免疫组化SP法检测脑胶质瘤标本Aurora-A激酶的表达,分析脑胶质瘤患者各临床因素与Aurora-A表达的关系. 结果脑胶质瘤组织中Aurora-A蛋白表达主要定位于胞浆和(或)胞核,本组脑胶质瘤标本Aurora-A阳性表达率为72.5％(29/40).不同病理级别、生存期的脑胶质瘤Aurora-A蛋白的表达不同,差异有统计学意义(P＜0.05)；脑胶质瘤的病理分级越高,Aurora-A的阳性表达率也越高,生存期≤3年患者脑胶质瘤中Aurora-A的阳性表达率高于生存期＞3年患者,差异均有统计学意义(P＜0.05). 结论脑胶质瘤存在Aurora-A蛋白高表达,且与肿瘤的预后有密切关系.其可能成为衡量脑胶质瘤预后的指标和新的治疗靶点.
목적 검측뇌효질류조직중Aurora-A적표체급기여환자각림상삼수지간적관계.방법 선취조경시제일인민의원신경외과자2010년6월지2012년8월적40례뇌효질류석사존당수술표본,기중WHO분급Ⅰ급8례、Ⅱ급8례、Ⅲ급10례、Ⅳ급14례.채용면역조화SP법검측뇌효질류표본Aurora-A격매적표체,분석뇌효질류환자각림상인소여Aurora-A표체적관계. 결과 뇌효질류조직중Aurora-A단백표체주요정위우포장화(혹)포핵,본조뇌효질류표본Aurora-A양성표체솔위72.5％(29/40).불동병리급별、생존기적뇌효질류Aurora-A단백적표체불동,차이유통계학의의(P＜0.05)；뇌효질류적병리분급월고,Aurora-A적양성표체솔야월고,생존기≤3년환자뇌효질류중Aurora-A적양성표체솔고우생존기＞3년환자,차이균유통계학의의(P＜0.05). 결론 뇌효질류존재Aurora-A단백고표체,차여종류적예후유밀절관계.기가능성위형량뇌효질류예후적지표화신적치료파점.
Objective To investigate the expression of Aurora-A in gliomas and its relationship with clinical significance of gliomas.Methods Forty glioma specimens kept with paraffin,including 8 with WHO grade Ⅰ,8 with WHO grade Ⅱ,10 with grade Ⅲ and 14 with grade Ⅳ,collected in our hospital from June 2010 to August 2012 during the surgery,were chosen in our study.The expression of Aurora-A was detected by immunohistochemistry in these 40 glioma specimens.The relationships between Aurora-A expression and clinical factors were analyzed.Results The Aurora-A protein expression mainly located in the cytoplasm and (or) nucleus; positive expression rate of Aurora-A was 72.5％ (29/40); the Aurora-A protein expression was significantly different in the glioma specimens of different pathological grades and different survival times of the patients:Aurora-A protein expression was positively related with pathological grades,and the Aurora-A protein expression in patients having survival time shorter than or equal to 3 years was significantly higher than that in patients having survival time longer than 3 years (P＜0.05).Conclusion Over-expression of Aurora-A in gliomas is correlated with prognosis of patients; Aurora-A maybe a potential marker for gliomas and a new therapy target.